Utilization and costs of antipsychotic agents: A Canadian population-based study, 1996-2006

Psychiatric Services

Volumn 59, Issue 5, 2008, Pages 547-553

  Alessi Severini, Silvia ^a   Biscontri, Robert G ^b   Collins, David M ^a   Kozyrskyj, Anita ^a   Sareen, Jitender ^a   Enns, Murray W ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; LEVOMEPROMAZINE; LOXAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PERICIAZINE; PERPHENAZINE; PIMOZIDE; PIPOTIAZINE; PROCHLORPERAZINE; QUETIAPINE; RISPERIDONE; THIOPROPERAZINE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE; ZUCLOPENTHIXOL;

ADOLESCENT; ADULT; AGED; ARTICLE; CANADA; CHILD; CONDUCT DISORDER; DATA BASE; DATA EXTRACTION; DEMENTIA; DRUG COST; DRUG MARKETING; DRUG USE; DRUG UTILIZATION; FEMALE; GROUPS BY AGE; HEALTH CARE COST; HUMAN; INFANT; MALE; NEWBORN; POPULATION RESEARCH; PRESCRIPTION; PREVALENCE; SCHIZOPHRENIA;

EID: 50849097069     PISSN: 10752730     EISSN: 15579700     Source Type: Journal    
DOI: 10.1176/ps.2008.59.5.547     Document Type: Article

References (31)

1. Kane J, Honingfeld G, Singer J, et al: Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Archives of General Psychiatry 45:789-796, 1988
2. Essock SM, Hargreaves WA, Covell NH, et al: Clozapine's effectiveness for patients in state hospitals: results from a randomized study. Psychopharmacology Bulletin 32:683-697, 1996
3. Leucht S, Pitschel-Walz G, Abraham D, et al: Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizophrenia Research 35:51-68, 1999
4. Correll CU, Leucht S, Kane JM: Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. American Journal of Psychiatry 161:414-425, 2004
5. Lehman AF, Lieberman JA, Dixon LB, et al: Practice guideline for the treatment of patients with schizophrenia: 2nd ed. American Journal of Psychiatry 161(Feb suppl):1-56, 2004
6. Addington D, Bouchard RH, Goldberg J, et al: Clinical practice guidelines: treatment of schizophrenia. Canadian Journal of Psychiatry 50(suppl 1):2S, 2005
7. Yathman LN, Kennedy SH, O'Donovan C, et al: Canadian Network for Mood and Anxiety Treatment (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disorders 8:721-739, 2006
8. Rosenheck R, Perlick D, Bingham S, et al: Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 290:2693-2702, 2003
9. Lieberman JA, Stroup TS, McEvoy JP, et al: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353:1209-1223, 2005
10. Gardner DM, Baldessarini RJ, Waraich P: Modern antipsychotic drugs: a critical overview. Canadian Medical Association Journal 172:1703-1711, 2005
11. Hanrahan P, Luchins DJ, Fabian R, et al: Cost-effectiveness of atypical antipsychotic medications versus conventional medication. Expert Opinion on Pharmacotherapy 7:1749-1758, 2006
12. Polsky D, Doshi J, Bauer M, et al: Clinical trial-based cost-effectiveness analyses of antipsychotic use. American Journal of Psychiatry 163:2017-2047, 2006
13. Wheeler A: Atypical antipsychotic use for adult outpatients in New Zealand's Auckland and Northland regions. New Zealand Medical Journal 119(1237):U2055, 2006
14. Rapoport M, Mamdani M, Shulman KI, et al: Antipsychotic use in the elderly: shifting trends and increasing costs. International Journal of Geriatric Psychiatry 20:749-753, 2005
15. Mamdani M, Rapoport M, Shulman KI, et al: Mental health-related drug utilization among older adults: prevalence, trends and costs. American Journal of Geriatric Psychiatry 13:892-900, 2005
16. Aparasu RR, Bhatara V, Gupta S: US national trends in the use of antipsychotics during office visits, 1998-2002. Annals of Clinical Psychiatry 17:147-152, 2005
17. Trifirò G, Spina E, Brignoli O, et al: Antipsychotic prescribing pattern among Italian general practitioners: a populationbased study during the years 1999-2002. European Journal of Clinical Pharmacology 61:47-53, 2005
18. Ganguly R, Kotzan JA, Miller LS, et al: Prevalence, trends and factors associated with antipsychotic Medicaid-eligible schizophrenia patients, 1998-2000. Journal of Clinical Psychiatry 65:1377-1388, 2004
19. Rochon PA, Stukel TA, Bronskill SE, et al: Variation in nursing home prescribing rates. Archives of Internal Medicine 167:676-683, 2007
20. Kogut SJ, Yam F, Dufresne R: Prescribing of antipsychotic medication in a Medicaid population: use of polytherapy and off-label dosages. Journal of Managed Care Pharmacy 11:17-24, 2005
21. Kozyrskyj A, Mustard, D: Validation of an electronic, population based prescription database. Annals of Pharmacotherapy 32:1152-1157, 1998
22. Percudani MM, Barbui C, Fortino I, et al: Antidepressant and antipsychotic drugs prescribing in Lombardy [in Italian]. Epidemiologia Psychiatrica 15:59-70, 2006
23. Stachnik JM, Nunn-Thompson C: Use of atypical antipsychotics in the treatment of autistic disorder. Annals of Pharmacotherapy 41:626-634, 2007
24. Aras S, Tas FV, Unlu G: Medication prescribing practices in a child and adolescent psychiatry outpatient clinic. Child: Care, Health and Development 33:482-490, 2007
25. Sareen J, Kirshner A, Lander M, et al: Do antipsychotics ameliorate or exacerbate obsessive compulsive disorder symptoms? A systematic review. Journal of Affective Disorders 82:167-174, 2004
26. Recupero PR, Rainey SE: Managing risk when considering the use of atypical antipsychotics for elderly patients with dementia-related psychosis. Journal of Psychiatric Practice 13:143-152, 2007
27. Schneider LS, Tariot PN, Dagerman KS, et al: Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. New England Journal of Medicine 355:1525-1538, 2006
28. Pharmacare: a program for today and tomorrow. News release. Winnipeg, Canada, Manitoba Health, 2006. Available at www.gov.mb.ca/health/pharmacare/ strategy.html
29. New program allows Pharmacare drug deductibles to be paid in monthly installments. News release. Winnipeg, Canada, Manitoba Health, 2006. Available at www.gov.mb.ca/chc/press/top/2006/05/2006-05-10-03.html
30. Manitoba Drug Benefits and Interchangeability Formulary. Winnipeg, Canada, Manitoba Health. Available at www.gov.mb.ca/health/mdbif/bulletins.html
31. Drug Expenditures in Canada, 1985 to 2006. Ottawa, Canadian Institute for Health Information, 2006. Available at sec ure.cihi.ca/cihiweb/dispPage.jsp? cwpage=AR80E&cwtopic=80